Novogen Announces Important Discovery in Regenerative Medicine Program

SYDNEY, Jan. 15, 2015 -- Novogen Limited (ASX:NRT; NASDAQ:NVGN), an Australian/US biotechnology company, today announced an important discovery in its regenerative medicine program that has delivered a key proof-of-concept step forward in the quest to develop drugs capable of stimulating the function of brain tissue stem cells.

Regenerative medicine is concerned with repairing or replacing tissue lost due to age, disease, damage or congenital defects. In the case of the brain, damage associated with stroke, head trauma or neurodegenerative disease represents a very significant unmet clinical need for such therapies.

Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact

Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies ---Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology

GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015  -- Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

Pharmacyclics Announces Preliminary 2014 U.S. Net Product Revenue Results and 2015 U.S. Net Product Revenue Outlook

SUNNYVALE, Calif., Jan. 12, 2015  -- Pharmacyclics, Inc. (PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.  For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA^® (ibrutinib) is expected to be approximately $492 million. For the fourth quarter of 2014, U.S. net product revenue is expected to be approximately $185 million, which would represent an approximately 31% sequential increase compared to the quarter ended September 30, 2014.

Celator® Pharmaceuticals Announces Publication Of Promising Phase 2 Data For CPX-351 In First Relapse Acute Myeloid Leukemia Patients

- Data Show Significant Survival Improvement with CPX-351 in Poor-Risk Patients -

EWING, N.J., Jan. 12, 2015 -- Celator Pharmaceuticals, Inc. (CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced the publication of Phase 2 data evaluating CPX-351 in adult patients with first-relapse acute myeloid leukemia (AML) in Cancer, a peer-reviewed journal of the American Cancer Society. The study manuscript entitled, "Phase 2, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML," appears in the January 15, 2015 issue.